Recombinant CDK4 anticorps (N-Term)

N° du produit ABIN7879590

L’anticorps anti-CDK4 Monoclonal Lapin est utilisé pour la détection de CDK4 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour Recombinant CDK4 anticorps (N-Term) (ABIN7879590)

Antigène: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp CDK4 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CDK4-7987R

Détail du produit anti-CDK4 anticorps

Épitope: N-Term

Fonction: CDK4 Antibody

Purification: Protein A/G affinity

Immunogène: A recombinant fragment corresponding to the N-terminal of human CDK4 protein was used as the immunogen for the CDK4 antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the CDK4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Aliquot the CDK4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur CDK4

Antigène: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Autre désignation: CDK4

Sujet: Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level. CCND1- CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth. CDK4 is highly expressed in highly differentiated and dedifferentiated liposarcomas, but rarely expressed in other benign liposarcomas and other sarcomas. CDK4 and MDM2 combined to differentiate between highly differentiated liposarcoma (+), dedifferentiated liposarcoma (+) and myxoid liposarcoma, pleomorphic liposarcoma, spindle lipoma, pleomorphic lipoma and other high-grade sarcomas.

UniProt: P11802

Pathways: Cycle Cellulaire, Mitotic G1-G1/S Phases, Regulation of Cell Size